Meyer Handelman Co. Decreases Position in Zimmer Biomet Holdings, Inc. $ZBH

Meyer Handelman Co. cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,169 shares of the medical equipment provider’s stock after selling 5,700 shares during the period. Meyer Handelman Co.’s holdings in Zimmer Biomet were worth $2,623,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZBH. Key Financial Inc lifted its stake in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. grew its position in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its position in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares during the last quarter. Root Financial Partners LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $31,000. Finally, Mather Group LLC. bought a new stake in Zimmer Biomet in the third quarter valued at approximately $36,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $90.26 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The firm has a market cap of $17.66 billion, a P/E ratio of 25.50, a P/E/G ratio of 1.81 and a beta of 0.58. The business’s 50 day moving average price is $92.09 and its 200-day moving average price is $93.81.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the prior year, the company earned $2.31 earnings per share. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of analyst reports. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. UBS Group reissued a “sell” rating and set a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Barclays cut their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a report on Thursday, February 12th. Finally, Weiss Ratings cut shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.